11.01.02
Endovasc Establishes NDC
Endovasc Ltd., Inc., Montgomery, TX, a biotechnology company with two cardiovascular drugs approved for final FDA Phase III trials, has established a new subsidiary called Nutriceutical Development Corporation (NDC), for its nicotine and/or lobeline-based non-prescription products. NDC will focus on stem cell recruitment-based nutraceuticals, effectively differentiating the company from traditional nutraceutical companies.
Endovasc Ltd., Inc., Montgomery, TX, a biotechnology company with two cardiovascular drugs approved for final FDA Phase III trials, has established a new subsidiary called Nutriceutical Development Corporation (NDC), for its nicotine and/or lobeline-based non-prescription products. NDC will focus on stem cell recruitment-based nutraceuticals, effectively differentiating the company from traditional nutraceutical companies.